Last reviewed · How we verify
Tovaxin
At a glance
| Generic name | Tovaxin |
|---|---|
| Also known as | Autologous TCV, T Cell Vaccine |
| Sponsor | Opexa Therapeutics, Inc. |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (Phase 1)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS (Phase 2)
- An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00 (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |